AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditionsOCALA, Fla., April...